Scancell
Scancell's mission is to develop products that stimulate the immune system to treat or prevent cancer.
Drug discovery – cancer
School of Medicine
Profile
Scancell’s mission is to develop products that stimulate the immune system to treat or prevent cancer.
In December 2006, Scancell sold its pipeline of direct killing monoclonal antibodies to Arana Therapeutics, an Australian biopharmaceutical company. The deal allowed Scancell to focus its efforts entirely on its innovative ImmunoBody® and Moditope® cancer vaccine programmes.
Scancell’s first clinical candidate drug, ImmunoBody® is a DNA vaccine which is being developed for the treatment of melanoma.
Scancell began trading on AIM in 2008.
News and press releases
Spin-out company launches that will revolutionise the power generation sector
- 10th April 2024 2:39 pm·
University spin-out named as a Bloomberg UK start-up to watch
- 25th October 2023 10:38 am·
Researchers develop new platform that could replace the use of animals in research
- 3rd August 2023 11:20 am·
Spin-out company launched to deliver gene therapy during bone repair surgery
- 13th June 2023 11:48 am·
Lewis Capaldi visits the Neupulse office to try out our wearable wrist device
- 30th January 2023 3:04 pm·
Neupulse raises £918k in a second round of funding
- 20th January 2023 1:05 pm·
Alevin wins Best Biotech Startup Company award at the prestigious OBN Awards 2022
- 19th November 2022 2:34 pm·
SurePulse and partners land £1.4m Innovate UK award
- 2nd November 2022 1:37 pm·
PBD Biotech raises further £2.4m for its breakthrough tuberculosis blood test
- 27th October 2022 11:40 am·
Nottingham trio share award for brain imaging innovation
- 27th October 2022 11:28 am·
Face and voice recognition technology set to transform diagnosis of perinatal depression
- 20th October 2022 4:01 pm·